Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: An alternative model

Urology

Volumn 54, Issue 2, 1999, Pages 220-224

  Catalona, William J ^a   Partin, Alan W ^b   Finlay, Judith A ^c   Chan, Daniel W ^b   Rittenhouse, Harry G ^c   Wolfert, Robert L ^c   Woodrum, David L ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c Hybritech Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; HUMANS; MALE; MIDDLE AGED; PALPATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032770605     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00185-5     Document Type: Article

References (14)

1. Smith D.S., Catalona W.J., Herschman J.D. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 276:1996;1309-1315.
2. Partin A.W., Kattan M.W., Subong E.N.P., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer a multi-institutional update . JAMA. 277:1997;1445-1451.
3. Pound C.R., Partin A.W., Epstein J.I. PSA following anatomical radical retropubic prostatectomy patterns of recurrence and cancer control . Urol Clin North Am. 24:1997;395-406.
4. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
5. Woodrum D.L., Brawer M.K., Partin A.W., et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 159:1998;5-12.
6. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease a prospective multicenter trial . JAMA. 279:1998;1542-1547.
7. Arcangeli C.G., Humphrey P.A., Smith D.S., et al. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology. 51:1998;558-565.
8. Pannek J., Rittenhouse H.G., Chan D.W., et al. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol. 159:1998;1238-1242.
9. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA. 277:1997;1452-1455.
10. Van Cangh P.J., De Nayer P., De Vischer L., et al. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1 8 to 10 ng/ml total PSA . Urology. 48:1996;67-70.
11. Woodrum D.L., York L. Two year stability of free and total PSA in frozen serum samples. Urology. 52:1998;247-251.
12. Humphrey P.A., Vollmer R.T. Intraglandular tumor extent and prognosis in prostate carcinoma application of a grid method to prostatectomy specimens . Hum Pathol. 21:1990;799-804.
13. Woodrum D.L., French C.M., Hill T.M., et al. Analytical performance of the Tandem(R)-R free PSA immunoassay measuring free prostate-specific antigen. Clin Chem. 43:1997;1203-1208.
14. Carlson G.D., Calvanese C.B., Childs S.J. The appropriate lower limit for the percent free prostate-specific antigen reflex range. Urology. 52:1998;450-454.